Intuitive Surgical (NASDAQ:ISRG) Downgraded by Erste Group Bank to “Hold”

Erste Group Bank cut shares of Intuitive Surgical (NASDAQ:ISRG) from a strong-buy rating to a hold rating in a research note released on Monday morning,Zacks.com reports.

A number of other research firms have also recently commented on ISRG. Truist Financial dropped their price target on shares of Intuitive Surgical from $666.00 to $605.00 and set a “buy” rating for the company in a research note on Monday. Citigroup lifted their price objective on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a report on Friday, January 24th. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $707.00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $522.00 to $650.00 in a report on Monday, December 2nd. Finally, Jefferies Financial Group lifted their price objective on shares of Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $611.86.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $492.06 on Monday. The company has a market capitalization of $175.26 billion, a price-to-earnings ratio of 76.76, a PEG ratio of 5.85 and a beta of 1.43. Intuitive Surgical has a one year low of $364.17 and a one year high of $616.00. The company’s fifty day moving average price is $564.39 and its 200-day moving average price is $531.62.

Insider Buying and Selling at Intuitive Surgical

In other news, VP Fredrik Widman sold 810 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $573.78, for a total value of $464,761.80. Following the transaction, the vice president now directly owns 473 shares of the company’s stock, valued at approximately $271,397.94. This trade represents a 63.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. This represents a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,754 shares of company stock valued at $17,691,621 over the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

A number of institutional investors have recently bought and sold shares of ISRG. Atala Financial Inc acquired a new stake in shares of Intuitive Surgical during the fourth quarter valued at about $25,000. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical during the fourth quarter valued at about $26,000. Parvin Asset Management LLC acquired a new stake in shares of Intuitive Surgical during the fourth quarter valued at about $26,000. BankPlus Trust Department acquired a new stake in shares of Intuitive Surgical during the fourth quarter valued at about $28,000. Finally, Hurley Capital LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at approximately $28,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.